FTC plots a look in­to the com­pet­i­tive im­pact of PBMs on drug prices, phar­ma­cies

The Fed­er­al Trade Com­mis­sion un­der chair Lina Khan has yet to take a big swing at drug prices and the mid­dle­men dri­ving them up, but that may soon change with a vote com­ing next week.

Next Thurs­day, the FTC will vote on whether to is­sue or­ders to the largest of these mid­dle­men, known as phar­ma­cy ben­e­fit man­agers, “to study the com­pet­i­tive im­pact of con­trac­tu­al pro­vi­sions, re­im­burse­ment ad­just­ments, and oth­er prac­tices af­fect­ing drug prices, in­clud­ing those prac­tices that may dis­ad­van­tage in­de­pen­dent or spe­cial­ty phar­ma­cies,” ac­cord­ing to a new agen­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER